Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 5:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Pulmonary Arterial Hypertension
Interventions: Riociguat (Adempas, BAY63-2521); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 49
States / cities: Phoenix, Arizona • Tucson, Arizona • Fresno, California + 38 more

Conditions: Prostate Cancer
Interventions: MRI-guided Transurethral Ultrasound Ablation; Device
Lead sponsor: Profound Medical Inc.; Other
Eligibility: 45 Years to 80 Years · Male only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 8
States / cities: Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 5 more

Conditions: Head and Neck Cancer
Interventions: ConformalFLASH irradiation; Radiation
Lead sponsor: IBA Proton Therapy, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Ischemia-Reperfusion Injury, Kidney Diseases
Interventions: Reparixin continuous infusion, reparixin intermittent infusion, placebo infusion; Drug · Other
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Philadelphia, Pennsylvania

Conditions: Non-small Cell Lung Cancer
Interventions: Not listed
Lead sponsor: St Elizabeth Healthcare; Other
Eligibility: 18 Years and older
Enrollment: 7,659 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Edgewood, Kentucky

Conditions: Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Endometrial Cancer, Ovary Cancer, Ovary Neoplasm, Ovary Disease, Ovary Metastasis, Ovarian Diseases, Ovarian Cancer Stage, Ovarian Epithelial Cancer, Ovarian Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Neoplasm Epithelial, Ovarian Cancer Recurrent, Endometrial Diseases, Endometrial Adenocarcinoma, Endometrial Carcinosarcoma, Endometrial Clear Cell Adenocarcinoma, Endometrioid Adenocarcinoma, Endometrial Neoplasms, Endometrial Cancer Recurrent, Endometrioid Tumor, Fallopian Tube Cancer, Peritoneal Cancer
Interventions: ELU001; Drug
Lead sponsor: Elucida Oncology; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 18
States / cities: Phoenix, Arizona • Fullerton, California • Jacksonville, Florida + 15 more

Conditions: Obesity
Interventions: Low-calorie diet, low-carbohydrate diet; Behavioral
Lead sponsor: Temple University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 307 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2008
U.S. locations: 3
States / cities: Denver, Colorado • St Louis, Missouri • Philadelphia, Pennsylvania

Conditions: Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
Interventions: Decitabine and Cedazuridine, Venetoclax; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cancer, Multiple Myeloma
Interventions: Bortezomib, Melphalan, Autologous PBSC Transplant; Drug · Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Prostate Cancer
Interventions: CyberKnife Boost; Radiation
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Alcohol Misuse
Interventions: Mobile Health Intervention to Reduce Alcohol Use Among Young Adults; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 25 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Acute-On-Chronic Liver Failure
Interventions: SMT + PE-A 5%, Standard Medical Treatment; Biological · Other
Lead sponsor: Instituto Grifols, S.A.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 10
States / cities: Coronado, California • Los Angeles, California • Atlanta, Georgia + 7 more

Conditions: Brain and Central Nervous System Tumors
Interventions: Temozolomide, Radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2022
U.S. locations: 45
States / cities: Phoenix, Arizona • Los Angeles, California • Newark, Delaware + 38 more

Conditions: Breast Cancer
Interventions: ptDNA, Tissue sample; Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Charcot-Marie-Tooth Disease, Type Ia
Interventions: Ascorbic acid (Vitamin C), placebo; Drug
Lead sponsor: Wayne State University; Other
Eligibility: 13 Years to 70 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 3
States / cities: Baltimore, Maryland • Detroit, Michigan • Rochester, New York

Conditions: HIV Infections
Interventions: Video (group-delivered video-based intervention), HCT; Behavioral
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 370 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
Interventions: Plixorafenib; Drug
Lead sponsor: Fore Biotherapeutics; Industry
Eligibility: 8 Years and older
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 30
States / cities: Beverly Hills, California • San Francisco, California • Westwood, Los Angeles, California + 23 more

Conditions: Respiratory Distress Syndrome in Premature Infant
Interventions: High flow nasal cannula, Nasal CPAP; Procedure
Lead sponsor: Sharp HealthCare; Other
Eligibility: 23 Weeks to 28 Weeks
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: San Diego, California

Conditions: Lymphoma
Interventions: enzastaurin, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 25
States / cities: Huntsville, Alabama • Beverly Hills, California • Greenbrae, California + 22 more

Conditions: Renal Cell Carcinoma
Interventions: nephrectomy; Procedure
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 618 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Urinary Tract Infection
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 65 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy Volunteers
Interventions: MF-HIIT, MF-only, HIIT-only, Sitting rest; Behavioral
Lead sponsor: Purdue University; Other
Eligibility: 10 Years to 12 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Hematologic Malignancies
Interventions: Allogeneic donor TCRαβ+/CD19+ cell-depleted peripheral blood mononuclear cells; Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 80 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Risk Behavior, HIV/AIDS, Medication Adherence, Substance Abuse
Interventions: CHRP-BB; Other
Lead sponsor: University of Connecticut; Other
Eligibility: 18 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Search by objective public record fields.

A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH)

Pivotal Study of MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer

A Pilot Study of Ultra-High Dose Rate (ConformalFLASH®), for Reirradiation of Carcinoma of the Head and Neck

Reparixin in Prevention of Delayed Graft Function After Kidney Transplantation

A Review of Low-Dose CT Lung Cancer Screenings in a Community-Based Healthcare System With High Incidence

A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

The Safety and Effectiveness of Low and High Carbohydrate Diets

Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study

Hypofractionated Stereotactic Body Radiation Therapy as a Boost to the Prostate

Mobile Alcohol Use Intervention

Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%

Temozolomide and Radiation Therapy in Treating Patients With Gliomas

Monitoring Plasma Tumor DNA in Early-Stage Breast Cancer

High Dose Ascorbic Acid Treatment of CMT1A

No Excuses/Sin Buscar Excusas Intervention to Reduce Latino Men's HIV Risks

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Physiological Changes With High-Flow Nasal Cannula

A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only

Retrospective Study on Referral Patterns for High Risk Patients Post Nephrectomy

Diagnosis of Subclinical Urinary Tract Infections Using Advanced Microbiome Survey Techniques in High Risk Trauma Patients

Acute Effects of High-intensity Interval Training With Mindfulness-based Recovery on Executive Function in Children

Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies

Testing an Integrated Bio-Behavioral Primary HIV Prevention Intervention Among High-Risk People Who Use Drugs